Consumer-facing businesses in the UK are bracing for a major shift in demand as new weight-loss pills receive regulatory approval. With Eli Lilly’s Foundayo gaining authorization last week and a tablet version of Wegovy already on the market, the landscape for retail and food sectors is changing. Data from an RSM UK survey indicates that 34% of consumers would prefer a pill over traditional injections, with that preference jumping to over 40% among younger generations.
The findings, which surveyed 2,000 people, suggest that high earners are particularly interested in the oral medication options. Approximately 58% of respondents earning over £80,000 annually expressed a willingness to try the pill format. This shift is not just about the medication delivery method but about the knock-on effects for personal spending habits. Users of GLP-1 treatments report changes to their daily routines, including smaller portion sizes, reduced alcohol intake, and fewer snacks.
Retailers must now consider how this trend impacts inventory management and product positioning. While some sectors may see pressure on traditional food and beverage sales, others like health, wellness, and supplements could gain market share. Analysts suggest the change represents a redistribution of consumer spending rather than an absolute reduction. Businesses that anticipate these patterns in consumer baskets will be better prepared as these drugs gain wider accessibility.
The regulatory approval of Foundayo by the Medicines and Healthcare products Regulatory Agency follows the June authorization of Wegovy tablets. While these drugs are not yet available through the NHS, their potential for lower costs compared to injectable versions makes them a significant market factor. Companies are now tasked with monitoring how these behavioral changes will translate into long-term shifts in consumption across the UK.